Insider Selling: Isis Pharmaceuticals SVP Sells 10,000 Shares of Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) SVP C Frank Bennett unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $35.02, for a total transaction of $350,200.00. Following the completion of the sale, the senior vice president now directly owns 2,866 shares of the company’s stock, valued at approximately $100,367. The transaction was disclosed in a document filed with the SEC, which is available at this link.
ISIS has been the subject of a number of recent research reports. Analysts at Goldman Sachs Group Inc. reiterated a “hold” rating on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Monday. They now have a $26.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) to $46.00 in a research note to investors on Monday. They now have a “positive” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.20.
Isis Pharmaceuticals (NASDAQ:ISIS) traded up 6.71% during mid-day trading on Monday, hitting $38.48. 4,140,218 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 52 week low of $7.56 and a 52 week high of $39.83. The stock’s 50-day moving average is $28.60 and its 200-day moving average is $24.24. The company’s market cap is $4.437 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 19.5% on a year-over-year basis. Analysts expect that Isis Pharmaceuticals will post $-0.56 EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.